New York is currently home to 4446 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)
Recruiting
This research trial is studying a combination of neoadjuvant radiotherapy (RT), immunotherapy (pembrolizumab) and chemotherapy for lymph node-positive, triple negative (TN) or hormone receptor positive/HER2-negative breast cancer. The names of the study interventions involved in this study are: * Radiation Therapy (RT) * Immunotherapy: Pembrolizumab (MK-3475) * Chemotherapies: * Paclitaxel * Doxorubicin (also called Adriamycin) * Cyclophosphamide * Carboplatin (optional, and in TN onl... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2024
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Triple Negative Breast Cancer, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Biopsy-proven, Positive Lymph Node(s)
The Effects of Entrainment on Respiratory Stability and Cerebral Oxygenation in Preterm Infants
Recruiting
Infants born prematurely at will be asked to participate in this randomized controlled trial at a corrected gestational age of 24-37 weeks. Infants will be randomly selected to each of the two groups: intervention and control. Infants in the treatment group will receive six intervention days over a two-week period, 3 sessions per week. Each intervention day consists of each of the two interventions in a random sequence: no intervention/silence and live ocean disc instrument intervention. The sou... Read More
Gender:
ALL
Ages:
Between 24 weeks and 37 weeks
Trial Updated:
03/15/2024
Locations: Mount Sinai Hospitals, New York, New York
Conditions: Prematurity
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
Recruiting
The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/15/2024
Locations: Montefiore Medical Center, Bronx, New York
Conditions: COVID-19
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: GSK Investigational Site, Bronx, New York
Conditions: Neoplasms
CorMatrix Cor TRICUSPID ECM Valve Replacement - Pivotal Study
Recruiting
The goal of this pivotal study is to demonstrate the safety and performance of the Cor TRICUSPID ECM (extracellular matrix) Valve (or Cor PEDIATRIC Tricuspid ECM Valve) for the surgical management of tricuspid valve disease and dysfunction in adult and pediatric patients. The main question(s) it aims to answer are: * whether the device may be implanted successfully and safely, and * whether the device effectively treats tricuspid valve disease and dysfunction through 12 months Participants wil... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/14/2024
Locations: Columbia University Irving Medical Center/New York Presbyterian, New York, New York
Conditions: Tricuspid Valve Disease, Tricuspid Valve Insufficiency
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
Recruiting
This is a phase 1/2 study of combined treatment with dupilumab (anti-IL-4Ra) and cemiplimab (anti-PD-1) in patients with early-stage, resectable non-small cell lung cancer (NSCLC). The study will include participants with a confirmed diagnosis of NSCLC who are deemed to be surgical candidates, or patients who have a smoking history and radiographic findings highly suggestive if a diagnosis of NSCLC who are scheduled to undergo diagnostic biopsy. On Day 1, participants will receive neoadjuvant th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Non-Small Cell Lung Cancer
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
Recruiting
The study is intended to assess the safety and efficacy of neoadjuvant combination of IPH5201 and durvalumab in addition to standard chemotherapy and adjuvant combination of IPH5201 and durvalumab in untreated patients with resectable, early-stage (stage II to IIIA) non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: Northwell Health Cancer Institute / Center for Novel Cancer Therapeutics, Lake Success, New York
Conditions: Non Small Cell Lung Cancer
Oxytocin Bolus Versus Infusion in Elective Cesarean Section"
Recruiting
Bolus administration of oxytocin is superior to infusion in time to achieving adequate uterine tone.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
03/13/2024
Locations: Stony Brook University, Stony Brook, New York
Conditions: Elective Cesarean Section
Effects of Contralateral Strength Training on Postoperative Strength Deficits in the Immobilized Lower Extremity
Recruiting
This is a prospective, randomized controlled trial that will enroll patients undergoing unilateral meniscal root repair or meniscus transplant. The objective of this study is to determine if immediate postoperative strength training of the contralateral (non-surgical) lower extremity reduces postoperative loss of strength in an immobilized lower extremity. After the completion of surgery, patients will be randomized to either the experimental treatment (Group 1) or control group (Group II)for p... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
03/13/2024
Locations: New York University School of Medicine, New York, New York
Conditions: Meniscus; Detachment, Current Injury
Exploring the Effects of Spinal Cord Stimulation in Parkinson's Disease.
Recruiting
Parkinson Disease (PD) patients experience a variety of motor issues such as walking difficulties, loss of balance, and freezing while walking, which impacts their quality of life. Some symptoms, like freezing of gait (FOG), do not respond to medications typically used to treat PD. Current surgical procedures used to alleviate PD symptoms also do not always improve FOG. Since many traditional therapies have failed for the treatment of FOG, researchers have proposed the use of newer treatments. R... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: Columbia University, New York, New York
Conditions: Parkinson Disease
177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors
Recruiting
This is a Phase I clinical trial to assess the safety and dosimetry profiles of 177Lu-DOTA-EB-TATE in patients with advanced, metastatic or inoperable, somatostatin receptor-positive, well-differentiated GEP-NETs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Neuroendocrine Tumors
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
Recruiting
This research study is evaluating whether primary palliative care is an alternative strategy to specialty palliative care for improving quality of life, symptoms, mood, coping, and end of life outcomes in patients with acute myeloid leukemia (AML).
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
03/12/2024
Locations: University of Rochester, Rochester, New York
Conditions: Relapsed Adult AML, Primary Refractory Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia